An Vo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
An Vo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adam Wolin
Beam Therapeutics, Cambridge, MA
1 shared publication - Akash Mishra
The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA
1 shared publication - Albert J. Fenoy
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead
1 shared publication - Chris Tang
The Feinstein Institutes for Medical Research
1 shared publication - Daniela Perani
Vita-Salute San Raffaele University
1 shared publication - David Eidelberg
The Feinstein Institutes for Medical Research
1 shared publication
Latest Publications
- Open Access
- 14 May 2025
- Published by Springer Nature in Research Square
Preoperative network activity predicts the response to subthalamic DBS for Parkinson’s disease
Quantitative imaging markers to aid in the selection of Parkinson’s disease (PD) patients for surgical interventions such as subthalamic nucleus deep brain stimulation (STN-DBS) are currently lacking. Using metabolic PET and network analysis we identified and validated a treatment-induced topography, termed STN StimNet. Stimulation-mediated changes in network expression correlated with concurrent motor improvement in independent STN-DBS cohorts scanned on and off stimulation. Moreover, STN StimNet measurements off stimulation correlated with local field potentials recorded from the STN, whereas intraoperative modulation of cortical activity by STN stimulation correlated with contributions to the network from corresponding brain regions. These findings suggested that stimulation-mediated clinical responses are influenced by baseline StimNet expression. Indeed, we found that motor outcomes following STN-DBS were predicted by preoperative network expression measured using metabolic PET or resting state fMRI. To illustrate the potential utility of these measures in selecting optimal candidates for DBS surgery, STN StimNet expression was computed in scans from 175 PD patients (0–21 years from diagnosis). The resulting values were used to identify those individuals likely to derive meaningful benefit from a potential STN-DBS procedure. This approach suggests that preoperative network quantification provides unique information regarding baseline brain circuitry, which may be useful in surgical decision making.
- 14 May 2025
- Published by Springer Nature in Research Square
Open AccessPreoperative network activity predicts the response to subthalamic DBS for Parkinson’s disease
Quantitative imaging markers to aid in the selection of Parkinson’s disease (PD) patients for surgical interventions such as subthalamic nucleus deep brain stimulation (STN-DBS) are currently lacking. Using metabolic PET and network analysis we identified and validated a treatment-induced topography, termed STN StimNet. Stimulation-mediated changes in network expression correlated with concurrent motor improvement in independent STN-DBS cohorts scanned on and off stimulation. Moreover, STN StimNet measurements off stimulation correlated with local field potentials recorded from the STN, whereas intraoperative modulation of cortical activity by STN stimulation correlated with contributions to the network from corresponding brain regions. These findings suggested that stimulation-mediated clinical responses are influenced by baseline StimNet expression. Indeed, we found that motor outcomes following STN-DBS were predicted by preoperative network expression measured using metabolic PET or resting state fMRI. To illustrate the potential utility of these measures in selecting optimal candidates for DBS surgery, STN StimNet expression was computed in scans from 175 PD patients (0–21 years from diagnosis). The resulting values were used to identify those individuals likely to derive meaningful benefit from a potential STN-DBS procedure. This approach suggests that preoperative network quantification provides unique information regarding baseline brain circuitry, which may be useful in surgical decision making.
- Open Access
- 25 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2091
The Impact of Muscarinic Antagonism on Psychosis-Relevant Behaviors and Striatal [11C] Raclopride Binding in Tau Mouse Models of Alzheimer’s Disease
Psychosis that occurs over the course of Alzheimer’s disease (AD) is associated with increased caregiver burden and a more rapid cognitive and functional decline. To find new treatment targets, studies modeling psychotic conditions traditionally employ agents known to induce psychosis, utilizing outcomes with cross-species relevance, such as locomotive activity and sensorimotor gating, in rodents. In AD, increased burdens of tau pathology (a diagnostic hallmark of the disease) and treatment with anticholinergic medications have, separately, been reported to increase the risk of psychosis. Recent evidence suggests that muscarinic antagonists may increase extracellular tau. Preclinical studies in AD models have not previously utilized muscarinic cholinergic antagonists as psychotomimetic agents. In this report, we utilize a human–mutant–tau model (P301L/COMTKO) and an over-expressed non-mutant human tau model (htau) in order to compare the impact of antimuscarinic (scopolamine 10 mg/kg/day) treatment with dopaminergic (reboxetine 20 mg/kg/day) treatment, for 7 days, on locomotion and sensorimotor gating. Scopolamine increased spontaneous locomotion, while reboxetine reduced it; neither treatment impacted sensorimotor gating. In the P301L/COMTKO, scopolamine treatment was associated with decreased muscarinic M4 receptor expression, as quantified with RNA-seq, as well as increased dopamine receptor D2 signaling, as estimated with Micro-PET [11C] raclopride binding. Scopolamine also increased soluble tau in the striatum, an effect that partially mediated the observed increases in locomotion. Studies of muscarinic agonists in preclinical tau models are warranted to determine the impact of treatment—on both tau and behavior—that may have relevance to AD and other tauopathies.
- 25 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2091
Open AccessThe Impact of Muscarinic Antagonism on Psychosis-Relevant Behaviors and Striatal [11C] Raclopride Binding in Tau Mouse Models of Alzheimer’s Disease
Psychosis that occurs over the course of Alzheimer’s disease (AD) is associated with increased caregiver burden and a more rapid cognitive and functional decline. To find new treatment targets, studies modeling psychotic conditions traditionally employ agents known to induce psychosis, utilizing outcomes with cross-species relevance, such as locomotive activity and sensorimotor gating, in rodents. In AD, increased burdens of tau pathology (a diagnostic hallmark of the disease) and treatment with anticholinergic medications have, separately, been reported to increase the risk of psychosis. Recent evidence suggests that muscarinic antagonists may increase extracellular tau. Preclinical studies in AD models have not previously utilized muscarinic cholinergic antagonists as psychotomimetic agents. In this report, we utilize a human–mutant–tau model (P301L/COMTKO) and an over-expressed non-mutant human tau model (htau) in order to compare the impact of antimuscarinic (scopolamine 10 mg/kg/day) treatment with dopaminergic (reboxetine 20 mg/kg/day) treatment, for 7 days, on locomotion and sensorimotor gating. Scopolamine increased spontaneous locomotion, while reboxetine reduced it; neither treatment impacted sensorimotor gating. In the P301L/COMTKO, scopolamine treatment was associated with decreased muscarinic M4 receptor expression, as quantified with RNA-seq, as well as increased dopamine receptor D2 signaling, as estimated with Micro-PET [11C] raclopride binding. Scopolamine also increased soluble tau in the striatum, an effect that partially mediated the observed increases in locomotion. Studies of muscarinic agonists in preclinical tau models are warranted to determine the impact of treatment—on both tau and behavior—that may have relevance to AD and other tauopathies.